{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:41:29Z","timestamp":1759963289159},"reference-count":36,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1840,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1600-0560.2010.01592.x","type":"journal-article","created":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T16:07:11Z","timestamp":1282147631000},"page":"no-no","source":"Crossref","is-referenced-by-count":6,"title":["Lupus erythematosus-like imiquimod reaction: a diagnostic pitfall*"],"prefix":"10.1111","author":[{"given":"Keira L.","family":"Barr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas H.","family":"Konia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxwell A.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,18]]},"reference":[{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"913.","DOI":"10.1097\/01.smj.0000176712.01491.98","article-title":"Current and potential uses of imiquimod.","volume":"98","author":"Chang","year":"2005","journal-title":"South Med J"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"554.","DOI":"10.1177\/120347540200600607","article-title":"Imiquimod: a review.","volume":"6","author":"Gupta","year":"2002","journal-title":"J Cutan Med Surg"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1657.","DOI":"10.2165\/00003495-200666130-00001","article-title":"The role of topical immune response modifiers in skin cancer.","volume":"66","author":"Woodmansee","year":"2006","journal-title":"Drugs"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"vii","DOI":"10.1016\/j.det.2004.08.007","article-title":"Imiquimod for the treatment of skin cancer.","volume":"23","author":"Burns","year":"2005","journal-title":"Dermatol Clin"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB5|cit5","first-page":"910.","article-title":"Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curretage.","volume":"6","author":"Neville","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"121.","DOI":"10.1080\/09546630600552323","article-title":"Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream.","volume":"17","author":"Goldenberg","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB7|cit7","first-page":"36.","article-title":"Mechanism of action and other potential roles of an immune response modifier.","volume":"79","author":"Gaspari","year":"2007","journal-title":"Cutis"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1743.","DOI":"10.1517\/14656566.8.11.1743","article-title":"Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.","volume":"8","author":"Papadavid","year":"2007","journal-title":"Expert Opin Pharmachother"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"227.","DOI":"10.1136\/sti.2005.018226","article-title":"A case of severe eczema following use of imiquimod 5% cream.","volume":"82","author":"Taylor","year":"2006","journal-title":"Sex Transm Infect"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB10|cit10","first-page":"125.","article-title":"Cutaneous histologic reaction after the use of imiquimod cream: a case report [Abstract].","volume":"37","author":"Barr","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"652.","DOI":"10.5858\/2008-132-652-ID","article-title":"Interface dermatitis.","volume":"132","author":"Crowson","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"211.","DOI":"10.1111\/j.1440-0960.2009.00541.x","article-title":"Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.","volume":"50","author":"Sriprakash","year":"2009","journal-title":"Australas J Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"878.","DOI":"10.1111\/j.1600-0560.2008.01134.x","article-title":"Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.","volume":"36","author":"Gowda","year":"2009","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"e60.","DOI":"10.1111\/j.1365-2230.2008.03181.x","article-title":"Pemphigus-like lesions induced by imiquimod.","volume":"34","author":"Bauza","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"331.","DOI":"10.1111\/j.0906-6705.2006.00414.x","article-title":"Immune response modifiers - mode of action.","volume":"15","author":"Schiller","year":"2006","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"639.","DOI":"10.1111\/j.1365-2230.2004.01614.x","article-title":"Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early infiltration by CD4 T cells and dendritic cells.","volume":"29","author":"Barnetson","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"72.","DOI":"10.1111\/j.1365-2133.2005.06932.x","article-title":"Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized control trial.","volume":"154","author":"Ooi","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"510.","DOI":"10.1001\/archderm.141.4.510","article-title":"Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.","volume":"141","author":"Wolf","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB19|cit19","first-page":"36.","volume-title":"Weedon's Skin Pathology.","author":"Weedon","year":"2010"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1324.","DOI":"10.1001\/archderm.1993.01680310094017","article-title":"Interface dermatitis. How specific are its histopathologic features?","volume":"129","author":"LeBoit","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB21|cit21","volume-title":"Histologic diagnosis of inflammatory skin diseases: an algorithmic method based on pattern analysis","author":"Ackerman","year":"2005"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1.","DOI":"10.1034\/j.1600-0560.2001.280101.x","article-title":"The cutaneous pathology of lupus erythematosus: a review.","volume":"28","author":"Crowson","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"312.","DOI":"10.1111\/j.1365-4632.2009.03916.x","article-title":"In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma.","volume":"48","author":"De Giorgi","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"291.","DOI":"10.1023\/B:APPT.0000025805.55340.c3","article-title":"Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod.","volume":"9","author":"Sch\u00f6n","year":"2004","journal-title":"Apoptosis"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1325.","DOI":"10.1001\/archderm.139.10.1325","article-title":"Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.","volume":"139","author":"Urosevic","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"222.","DOI":"10.1186\/ar2321","article-title":"Toll-like receptors and innate immune responses in systemic lupus erythematosus.","volume":"9","author":"Lafyatis","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"251.","DOI":"10.1111\/j.1600-065X.2007.00572.x","article-title":"Toll-like receptors 7, 8 and 9: linking innate immunity to autoimmunity.","volume":"220","author":"Krieg","year":"2007","journal-title":"Immunol Rev"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"204.","DOI":"10.1016\/j.autrev.2008.07.046","article-title":"Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention.","volume":"8","author":"Wan-uk","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"2610.","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1497.","DOI":"10.1001\/archderm.136.12.1497","article-title":"Detection of type cytokines in discoid lupus erythematosus.","volume":"136","author":"Toro","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"191.","DOI":"10.1016\/S0190-9622(97)70279-2","article-title":"T-cell cytokine network in cutaneous lupus erythematosus.","volume":"36","author":"Stein","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"439.","DOI":"10.1111\/j.1600-0560.2009.01424.x","article-title":"Oral lesions in lupus erythematosus-cytokines profiles of inflammatory infiltrate.","volume":"37","author":"Marques","year":"2010","journal-title":"J Cutan Pathol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1138.","DOI":"10.1093\/jnci\/djg016","article-title":"Tumor-selective induction of apoptosis and the small-molecular immune response modifier imiquimod.","volume":"95","author":"Sch\u00f6n","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"518.","DOI":"10.1111\/j.1365-2230.2004.01601.x","article-title":"Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.","volume":"29","author":"Vidal","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"656.","DOI":"10.1111\/j.1365-2133.2004.06094.x","article-title":"Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis.","volume":"151","author":"Vidal","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1600-0560.2010.01592.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"59.","DOI":"10.1046\/j.0366-077X.2003.05634.x","article-title":"Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.","volume":"149","author":"Berman","year":"2003","journal-title":"Br J Dermatol"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0560.2010.01592.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0560.2010.01592.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T12:33:48Z","timestamp":1636202028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0560.2010.01592.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,18]]},"references-count":36,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0560.2010.01592.x","relation":{},"ISSN":["0303-6987"],"issn-type":[{"value":"0303-6987","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8,18]]}}}